Details of Disease

General Information of Disease (ID: DISOZNA3)

Disease Name Influenza A virus H5N1 infection
Disease Class 1E30-1E32: Influenza
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISOZNA3: Influenza A virus H5N1 infection
ICD Code
ICD-11
ICD-11: 1E30
Expand ICD-11
1.00E+31
Expand ICD-9
487488

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
KD-295 DM91OR1 Registered NA [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Influenza A virus vaccine H5N1 DM0FUFN Phase 2 NA [2]
Aflunov DMMNIBY Phase 1/2 Vaccine [3]
H5N1 influenza virus vaccine DMJ5W3I Phase 1/2 NA [4]
Influenza A virus H5N1 cell culture-based vaccine DMKRQ5V Phase 1 NA [1]
INO-3401 DM90P1K Phase 1 Vaccine [5]
Pre-pandemic Avian influenza vaccine DMOVVTX Phase 1 NA [6]
VGX-3400 DMGMEH7 Phase 1 Vaccine [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033836)
2 iBio Announces Positive H1N1 Influenza Vaccine Clinical Trial Results. iBio, Inc. June 2, 2011.
3 ClinicalTrials.gov (NCT00814385) Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of Novavax.
5 ClinicalTrials.gov (NCT01405885) A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus. U.S. National Institutes of Health.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT01142362) Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults. U.S. National Institutes of Health.